上海岸迈生物与浙江特瑞思宣布合作开发岸迈生物双特异性抗体项目FIT012
浙江特瑞思将获得该产品中国开发权益，岸迈生物将拥有该产品除中国地区外的全球商业权益
2018.4.23 中国上海/苏州，湖州----岸迈生物科技有限公司，一家总部位于上海的专注于双特异性抗体开发的新兴生物制药公司，以及浙江特瑞思药业股份有限公司，一家专门从事生物制剂研发的制药公司，今天宣布将合作开发一项由岸迈生物开发的双特异性抗体项目。根据双方合作协议条款，浙江特瑞思药业股份有限公司将获得岸迈生物的FIT-Ig®双抗项目FIT012 / TRS008的中国市场开发权益。岸迈生物将保留该项目除中国以外的全球商业权益。作为对中国商业化权益的回报，岸迈生物将获得包括预付款在内总额高达2100万美元的里程碑付款，以及后续产品销售提成。同时，岸迈生物将可能使用浙江特瑞思所提供的产品数据，用于在中国以外地区的产品开发或授权。
“除了岸迈生物目前正在进入临床开发的领头产品EMB01之外，FIT012将是岸迈目前经过验证的双抗产品中进入临床前和临床开发的又一优秀案例。”岸迈生物首席执行官兼创始人吴辰冰博士表示，“特瑞思是该创新项目的理想合作伙伴，公司已经证明了其在CMC方面的卓越能力，同时还拥有出色的早期临床开发能力及多项成功IND申请的记录。”
FIT012 / TRS008是一项针对肿瘤治疗的双特异性抗体项目。该项目是由岸迈生物开发并由特瑞思公司在一系列临床前试验中进行了验证。FIT012 / TRS008的靶点目标目前没有披露。
“我们很高兴与岸迈生物合作开发这个创新项目。 FIT012 / TRS008将非常适合我们公司的产品开发管线，” 浙江特瑞思药业股份有限公司首席执行官兼创始人吴幼玲表示，“除了我们公司自有的丰富的生物仿制药和创新抗体产品管线外，像FIT012 / TRS008这一类高度创新的双特异性抗体将让我们能够进一步扩大我们的产品管线。“
--欢迎和我们在第10届生命科学合作会议ChinaBio®合作论坛上见面---岸迈生物将在星期三下午2点（2018年4月25）发表演讲---欲了解更多信息，请访问：
https://ebdgroup.knect365.com/chinabio-partnering/
关于岸迈生物科技有限公司
岸迈生物科技有限公司（EpimAb Biotherapeutics, Inc.）是一家私有的生物制药研发公司，总部位于上海，其自主研发的FIT-Ig®(Fabs-In-Tandem Immunoglobulin)技术是一项独特高效的开发双特异性抗体产品的平台技术。基于该技术平台，岸迈生物将开发一系列创新的双抗药物，主要针对肿瘤免疫和其他对于患者具备重要价值的治疗领域。岸迈生物同时也将致力通过有选择性的技术平台授权，在全球范围积极拓展多元化的合作。如需进一步信息，请访问www.epimab.com
关于浙江特瑞思药业股份有限公司
浙江特瑞思药业股份有限公司（Zhejiang Teruisi Biopharmaceutical, Inc.）是一家以中国为基地的制药公司，公司致力于开发生物大分子药物，专注但不限于单克隆抗体产品开发以及其他生物药商业生产，如生物仿制药和创新生物药等。凭借其强大的研发背景和专业知识，特瑞思期待着在生物制药领域寻求全球合作伙伴。
EpimAb Biotherapeutics and Zhejiang Teruisi Biopharmaceutical Announce Development Collaboration on Epimab’s FIT012 Bispecific Antibody Program
ZHEJIANG TERUISI BIOPHARMACEUTICAL TO TAKE THE LEAD IN DEVELOPING THE PROGRAM IN CHINA, EPIMAB RETAINS WORLDWIDE COMMERCIAL RIGHTS OUTSIDE OF CHINA
Shanghai/Suzhou, and Huzhou, China, April 23, 2018 - EpimAb Biotherapeutics, a Shanghai-based biopharmaceutical company specializing in bispecific antibodies, and Zhejiang Teruisi Biopharmaceutical, a company specialized in the development of biologics, today announced a development collaboration on a bispecific antibody program discovered by EpimAb. Under the terms of the agreement, Zhejiang Teruisi Biopharmaceutical, Inc. will gain access to EpimAb’s Fabs-In-Tandem Immunoglobulin (FIT-Ig®) program FIT012/TRS008 to develop it for the Chinese market. EpimAb retains all commercial rights to the program outside of China. In return for commercialization rights in China, EpimAb is eligible to receive an upfront payment and total success-based milestones of up to US-$21 MM, plus royalties. EpimAb may use the development data generated by Zhejiang Teruisi in partnering discussions outside of China for an undisclosed share of its net receipts. Further financial details were not disclosed.
“In addition to EMB01, EpimAb’s frontrunner program that is on its way to clinical development, FIT012 is another great example of EpimAb’s first validated assets moving forward into preclinical and clinical development,” said Dr. Chengbin Wu, CEO and founder of EpimAb. “Teruisi is an ideal partner for this innovative program and has proven its excellence in CMC capabilities with a successful track record of multiple IND filings as well as early clinical development.”
FIT012/TRS008 is a bispecific antibody program in oncology. The molecule was identified by EpimAb and validated by Zhejiang Teruisi Biopharmaceutical in an extensive series of preclinical tests. The targets of FIT012/TRS008 were not disclosed.
“We are delighted to work with EpimAb on this innovative program. FIT012/TRS008 will fit nicely in our development pipeline,” said Youling Wu, Chief Executive Officer and Founder of Zhejiang Teruisi Biopharmaceutical, Inc. “In addition to our rich pipeline of biosimilars and novel antibodies, a highly innovative bispecific antibody like FIT012/TRS008 will allow us to further expand our pipeline.”
--- Meet us at the 10th Annual International ChinaBio® Partnering Forum --- Epimab will present on Wednesday, 25 April 2018 at 2:00 pm CST --- For more info, please visit: https://ebdgroup.knect365.com/chinabio-partnering/
About EpimAb Biotherapeutics, Inc.
EpimAb Biotherapeutics is a privately-owned biopharmaceutical R&D company based in Shanghai with a proprietary unique and efficient technology called FIT-Ig® (Fabs-In-Tandem Immunoglobulin) to generate bispecific molecules with antibody-like properties. With this platform EpimAb is creating a pipeline of its own novel bispecific antibody therapeutics focused around immuno-oncology and other areas of high value to patients. EpimAb is also committed to diversifying its pipeline through selective licensing of its platform and pipeline assets to partners worldwide. For further information, please visit : www.epimab.com
About Zhejiang Teruisi Biopharmaceutical, Inc.
ZheJiang Teruisi Biopharmaceutical, Inc. is a Chinese based company that is developing biopharmaceuticals focusing on, but not limited, to monoclonal antibody product development and commercial manufacturing including biosimilars and innovate biopharmaceuticals. With its strong knowledge and expertise, Teruisi is looking forward to seeking partners worldwide in biopharmaceutical development.
Contact
EpimAb Biotherapeutics
Dr. Stephan Lensky, COO/CBO
Direct: +49 152 2610 7621
E-Mail: Stephan.lensky@epimab.com
ZheJiang Teruisi Biopharmaceutical
Dr. Youling Wu, CEO
Direct: +86 186 6810 9601
E-Mail: youling.wu@teruisipharm.com
For media:
MacDougall Biomedical Communications
Mario Brkulj or Amanda Houlihan
+49 89 2420 9345
or +1 781-235-3060
epimab@macbiocom.com
